1,444 results on '"Kung, Andrew L."'
Search Results
202. Successful treatment and integrated genomic analysis of an infant with FIP1L1-RARA fusion-associated myeloid neoplasm.
203. Targeting MTHFD2 in acute myeloid leukemia
204. Expression-Based Screening Identifies the Combination of Histone Deacetylase Inhibitors and Retinoids for Neuroblastoma Differentiation
205. Crebbp haploinsufficiency in mice alters the bone marrow microenvironment, leading to loss of stem cells and excessive myelopoiesis
206. Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor
207. MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L
208. BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
209. Green tea epigallocatechin-3-gallate inhibits angiogenesis and suppresses vascular endothelial growth factor C/vascular endothelial growth factor receptor 2 expression and signaling in experimental endometriosis in vivo
210. Dynamic Network Curvature Analysis of RNA-Seq Data in Sarcoma
211. Successful treatment and integrated genomic analysis of an infant with FIP1L1-RARA fusion–associated myeloid neoplasm
212. Antithymocyte globulin exposure in CD34+ T-cell–depleted allogeneic hematopoietic cell transplantation
213. Using Glow Stick Chemistry for Biological Imaging
214. Predictors for Recent Thymic Emigrant T Cell Reconstitution after Hematopoietic Cell Transplantation
215. Regulatory T Cell Reconstitution Is Associated with Acute Graft-Versus-Host Disease in Pediatric and Young Adult Hematopoietic Cell Transplant Recipients
216. Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRα, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants
217. A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53
218. An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells
219. Bone Marrow Surveillance of Pediatric Cancer Survivors Identifies Clones that Predict Therapy-Related Leukemia
220. An RNA-Based Precision Oncology Platform for Patient-Therapy Alignment in a Diverse Set of Treatment Resistant Malignancies
221. Systematic in vivo structure-function analysis of p300 in hematopoiesis
222. Human herpesvirus-6 viremia is not associated with poor clinical outcomes in children following allogeneic hematopoietic cell transplantation
223. Overcoming challenges to meaningful informed consent for whole genome sequencing in pediatric cancer research
224. Identification of AML1-ETO modulators by chemical genomics
225. The F-box Protein β-TrCp1/Fbw1a Interacts with p300 to Enhance β-Catenin Transcriptional Activity
226. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy
227. HOXA9 is required for survival in human MLL-rearranged acute leukemias
228. Proteomic and Genetic Approaches Identify Syk as an AML Target
229. Glioblastoma Inhibition by Cell Surface Immunoglobulin Protein EWI-2, In Vitro and In Vivo
230. Cell Line-Specific Differences in the Control of Cell Cycle Progression in the Absence of Mitosis
231. In vivo Inhibition of Cyclin B Degradation and Induction of Cell-Cycle Arrest in Mammalian Cells by the Neutral Cysteine Protease Inhibitor N- Acetylleucylleucylnorleucinal
232. Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities
233. New cast for a new era: preclinical cancer drug development revisited
234. Vascular endothelial growth factor C is increased in endometrium and promotes endothelial functions, vascular permeability and angiogenesis and growth of endometriosis
235. Bromodomain 4 inhibition leads to MYCN downregulation in Wilms tumor
236. Pre-clinical validation of an RNA-based precision oncology platform for patient-therapy alignment in a diverse set of human malignancies resistant to standard treatments
237. Identification and validation of a non-genetically encoded vulnerability to XPO1 inhibition in malignant rhabdoid tumors – expanding patient-driven discovery beyond the N-of-1
238. Translational Strategies for Repotrectinib in Neuroblastoma
239. Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer
240. A Bayesian active learning platform for scalable combination drug screens
241. Incongruity of Imaging Using Fluorescent 2-DG Conjugates Compared to 18F-FDG in Preclinical Cancer Models
242. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia
243. A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers
244. A D e Novo Supernumerary Ring Chromosome 1 Causes B-Cell Acute Lymphoblastic Leukemia in Monozygotic Twins Due to Independent and Partially Convergent Evolutionary Trajectories
245. Enhancing Myeloid Cancer Genomic Profiling through Comprehensive Whole Genome Sequencing Using the Isabl Gxt Heme Analytical Platform
246. The intersection of genetic and chemical genomic screens identifies GSK-3 α as a target in human acute myeloid leukemia
247. Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells
248. Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas
249. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL– and mutant FLT3-expressing cells
250. regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.